Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Division of Health Behavior and Health Promotion, College of Public Health, The Ohio State University, Columbus, OH, USA.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2172276. doi: 10.1080/21645515.2023.2172276. Epub 2023 Feb 7.
Proactive HPV vaccination at age 9 better prevents infection and improves vaccine series completion. Because national organizations recommend starting the vaccine at different ages, we sought to understand the impact of these recommendation frames. In 2022, we surveyed 2,527 US clinical staff (45% physicians) who provide HPV vaccine for children. We randomized respondents to one of three frames based on HPV vaccine recommendations of national organizations or a no-recommendation control, and assessed willingness to recommend HPV vaccine for children ages 9-10. Respondents also reported perceived benefits of HPV vaccination at ages 9 or 12. Recommending HPV vaccination "at ages 11-12" led to lower willingness to vaccinate at ages 9-10 than control (37% vs. 54%, < .05). Recommending vaccination "at ages 9-12" led to similar willingness as control. However, "starting at age 9" led to higher willingness than control (63% vs. 54%, < .05). Results were similar across respondents' training, specialty, or years in practice, or their clinic's rurality or healthcare system membership. More common benefits of recommending at age 9 than 12 were avoiding the topic of sex (24% vs. 10%, OR = 2.78, 95%CI: 2.23, 3.48) and completing the vaccine series before age 13 (56% vs. 47%, OR = 1.44, 95%CI: 1.23, 1.68). Less common benefits for age 9 were having parents ready to talk about HPV vaccine and agreeing to vaccination (both < .05). An effective way to encourage proactive HPV vaccination is to say that it starts at age 9. Aligning national recommendations to start at age 9 can promote timely vaccination.
在 9 岁时主动接种 HPV 疫苗可以更好地预防感染并完成疫苗系列接种。由于国家组织建议在不同年龄段开始接种疫苗，因此我们试图了解这些推荐框架的影响。2022 年，我们调查了 2527 名为儿童提供 HPV 疫苗的美国临床医务人员（45%为医生）。我们将受访者随机分配到三种框架之一，这些框架基于国家组织的 HPV 疫苗建议或无建议对照，并评估了他们为 9-10 岁儿童推荐 HPV 疫苗的意愿。受访者还报告了在 9 岁或 12 岁时接种 HPV 疫苗的感知益处。建议在 11-12 岁时接种 HPV 疫苗比对照组（37%比 54%， < .05）导致接种意愿降低。建议在 9-12 岁时接种疫苗与对照组相似。然而，“从 9 岁开始”比对照组更愿意接种（63%比 54%， < .05）。结果在受访者的培训、专业、从业年限、诊所的农村性或医疗保健系统成员资格方面相似。建议在 9 岁时接种疫苗比 12 岁时更常见的好处是避免讨论性话题（24%比 10%，OR = 2.78，95%CI：2.23，3.48）和在 13 岁之前完成疫苗系列接种（56%比 47%，OR = 1.44，95%CI：1.23，1.68）。建议在 9 岁时接种疫苗不太常见的好处是父母已经准备好讨论 HPV 疫苗并同意接种（均 < .05）。鼓励主动接种 HPV 疫苗的有效方法是说它从 9 岁开始。将国家建议调整为 9 岁开始可以促进及时接种疫苗。
